JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Ren, Yuan ^a   Zhang, Yonghong ^a   Liu, Richard Z ^a   Fenstermacher, David A ^a,b   Wright, Kenneth L ^a,b   Teer, Jamie K ^a,b   Wu, Jie ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CYSTEINE PROTEINASE; GAMMA INTERFERON; HLA ANTIGEN; JANUS KINASE 1; LMP 2 PROTEIN; LMP-2 PROTEIN; PROTEIN TYROSINE KINASE; TAP1 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; FEMALE GENITAL TRACT TUMOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE ENDOPEPTIDASES; DNA MUTATIONAL ANALYSIS; FEMALE; GENITAL NEOPLASMS, FEMALE; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; JANUS KINASE 1; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84895910321     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03042     Document Type: Article

References (30)

1. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 12, 175-80 (2011)
2. Gilliland, D. G., Jordan, C. T. & Felix, C. A. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program), 80-97 (2004)
3. Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-53 (2005)
4. Tefferi, A. &Gilliland, D. G. Oncogenes in myeloproliferative disorders. Cell Cycle 6, 550-66 (2007)
5. Jatiani, S. S., Baker, S. J., Silverman, L. R. & Reddy, E. P. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 1, 979-93 (2010)
6. Tefferi, A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119, 2721-30 (2012)
7. Gordon, G. M., Lambert, Q. T., Daniel, K. G. & Reuther, G. W. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-gamma. Biochem J 432, 255-65 (2010)
8. Seliger, B., Ruiz-Cabello, F. & Garrido, F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101, 249-76 (2008)
9. Wall, L., Burke, F., Barton, C., Smyth, J. & Balkwill, F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 9, 2487-96 (2003)
10. Kaplan, D. H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95, 7556-61 (1998)
11. Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75, 163-89 (2004)
12. Wright, K. L. et al. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med 181, 1459-71 (1995)
13. Gaczynska, M., Rock, K. L. & Goldberg, A. L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264-7 (1993)
14. Hayashi, T.&Faustman, D. L. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 62, 24-7 (2002)
15. Hayashi, T. et al. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep 1, 180 (2011)
16. Fenstermacher, D. A., Wenham, R. M., Rollison, D. E. & Dalton, W. S. Implementing personalized medicine in a cancer center. Cancer J 17, 528-36 (2011)
17. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-7 (2012)
18. Yu, H. & Jove, R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4, 97-105 (2004)
19. de la Salle, H. et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 265, 237-41 (1994)
20. Van Kaer, L., Ashton-Rickardt, P. G., Ploegh, H. L. & Tonegawa, S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-81 T cells. Cell 71, 1205-14 (1992)
21. Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013)
22. Li, H. &Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-60 (2009)
23. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43, 491-8 (2011)
24. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164 (2010)
25. Lunter, G. & Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res 21, 936-9 (2011)
26. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-9 (2009)
27. Cunnick, J. M. et al. Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J Biol Chem 273, 14468-75 (1998)
28. Xu, C. X. et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 287, 34970-8 (2012)
29. Ren, Y. et al. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer 1, 994-1007 (2010)
30. Ren, Y. et al. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem 282, 36463-73 (2007)